» Articles » PMID: 26951646

Three-dimensional Bioprinting of Thick Vascularized Tissues

Overview
Specialty Science
Date 2016 Mar 9
PMID 26951646
Citations 503
Authors
Affiliations
Soon will be listed here.
Abstract

The advancement of tissue and, ultimately, organ engineering requires the ability to pattern human tissues composed of cells, extracellular matrix, and vasculature with controlled microenvironments that can be sustained over prolonged time periods. To date, bioprinting methods have yielded thin tissues that only survive for short durations. To improve their physiological relevance, we report a method for bioprinting 3D cell-laden, vascularized tissues that exceed 1 cm in thickness and can be perfused on chip for long time periods (>6 wk). Specifically, we integrate parenchyma, stroma, and endothelium into a single thick tissue by coprinting multiple inks composed of human mesenchymal stem cells (hMSCs) and human neonatal dermal fibroblasts (hNDFs) within a customized extracellular matrix alongside embedded vasculature, which is subsequently lined with human umbilical vein endothelial cells (HUVECs). These thick vascularized tissues are actively perfused with growth factors to differentiate hMSCs toward an osteogenic lineage in situ. This longitudinal study of emergent biological phenomena in complex microenvironments represents a foundational step in human tissue generation.

Citing Articles

Lymphoma-on-chip model reveals that lymph node stromal cells promote diffuse large B-cell lymphoma survival and migration.

Jouybar M, Mikula A, Zuidmeer N, Konijn T, de Jonge A, Roest H Mater Today Bio. 2025; 31:101544.

PMID: 40061210 PMC: 11889632. DOI: 10.1016/j.mtbio.2025.101544.


Hydrogels and Nanogels: Pioneering the Future of Advanced Drug Delivery Systems.

Delgado-Pujol E, Martinez G, Casado-Jurado D, Vazquez J, Leon-Barberena J, Rodriguez-Lucena D Pharmaceutics. 2025; 17(2).

PMID: 40006582 PMC: 11859140. DOI: 10.3390/pharmaceutics17020215.


3D bioprinting for the production of a perfusable vascularized model of a cancer niche.

Maggiotto F, Bova L, Micheli S, Pozzer C, Fusco P, Sgarbossa P Front Bioeng Biotechnol. 2025; 13:1484738.

PMID: 39980862 PMC: 11841441. DOI: 10.3389/fbioe.2025.1484738.


Development of a Novel Hybprinter-SAM for Functionally Graded Tissue Engineering Constructs with Patterned and Localized Biochemical Signals.

Yang Y, Li J, Kim C, Alizadeh H, Garg S, Alizadeh H Res Sq. 2025; .

PMID: 39975888 PMC: 11838729. DOI: 10.21203/rs.3.rs-5898561/v1.


Bioprinting approaches in cardiac tissue engineering to reproduce blood-pumping heart function.

Kim M, Hwang D, Jang J iScience. 2025; 28(1):111664.

PMID: 39868032 PMC: 11763539. DOI: 10.1016/j.isci.2024.111664.


References
1.
Giulitti S, Magrofuoco E, Prevedello L, Elvassore N . Optimal periodic perfusion strategy for robust long-term microfluidic cell culture. Lab Chip. 2013; 13(22):4430-41. DOI: 10.1039/c3lc50643f. View

2.
Lee K, Mooney D . Hydrogels for tissue engineering. Chem Rev. 2001; 101(7):1869-79. DOI: 10.1021/cr000108x. View

3.
Murphy S, Atala A . 3D bioprinting of tissues and organs. Nat Biotechnol. 2014; 32(8):773-85. DOI: 10.1038/nbt.2958. View

4.
Bhatia S, Ingber D . Microfluidic organs-on-chips. Nat Biotechnol. 2014; 32(8):760-72. DOI: 10.1038/nbt.2989. View

5.
Abbott R, Kaplan D . Strategies for improving the physiological relevance of human engineered tissues. Trends Biotechnol. 2015; 33(7):401-7. PMC: 4475434. DOI: 10.1016/j.tibtech.2015.04.003. View